Absorption, Distribution, Metabolism And Excretion Study For GSK221149A
Phase 1
Completed
- Conditions
- Obstetric Labour, PrematurePremature Labor
- Registration Number
- NCT00457925
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
This is a phase one study investigating the absorption, distribution, metabolism and excretion of GSK221149A in six healthy women of non-child bearing potential.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 6
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Urinary and fecal cumulative excretion as a percentage of the total radioactive dose administered over time. Collection of plasma, urine and fecal samples for assessment of metabolites. Samples are collected for approximately 7 days (or longer).
- Secondary Outcome Measures
Name Time Method Clinical Safety data. PK parameters of GSK221149A and drug-related material (radioactivity) in plasma following oral and intravenous dosing. Samples are collected for approximately seven days (or longer) following dosing.
Trial Locations
- Locations (1)
GSK Investigational Site
🇺🇸Madison, Wisconsin, United States
GSK Investigational Site🇺🇸Madison, Wisconsin, United States